JAK2 Exons 12-15

JAK2 mutations were not detected in exons 12, 13, 14 and 15. This result does not rule out the presence of JAK2 mutation at a level below the detection sensitivity of this assay, the presence of other mutations outside the analyzed region of the JAK2 gene, or the presence of a myeloproliferative or other neoplasm. Result must be correlated with other clinical data for the most accurate diagnosis.

Indications
POLYCYTHEMIA VERA

Specimen Type
Blood

Background
JAK2 V617F mutation is detected in patients with polycythemia vera (95%), essential thrombocythemia (50%) and primary myelofibrosis (50%). A small percentage of JAK2 mutation positive patients (3.3%) contain other non-V617F mutations within exons 12 to 15. The detection of a JAK2 gene mutation aids in the specific diagnosis of a myeloproliferative neoplasm, and help distinguish this clonal disease from a benign reactive process.

Method
Total RNA was purified from the provided specimen. The JAK2 gene region covering exons 12 to 15 was subjected to reverse-transcription coupled PCR amplification, and bi-directional sequencing to identify sequence variations. This assay has a sensitivity to detect approximately 15% population of cells containing the JAK2 mutations in a background of non-mutant cells. This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

References
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
</table>
| Li Cai, PhD, FACMG  
Director, Molecular Genetics  
LabCorp Center for Molecular Biology and Pathology  
Research Triangle Park, NC  
1-800-533-0567 | 01 | | | | |
| 01 YU LabCorp RTP  
1904 TW Alexander Drive Suite C, RTP, NC 27709-0153 | | | | | Dir: Arundhati Chatterjee, MD |
| 02 TG LabCorp RTP  
1912 TW Alexander Drive, RTP, NC 27709-0150 | | | | | Dir: Arundhati Chatterjee, MD |

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-282-7300
**General Comments & Additional Information**

**Clinical Info:** ABNORMAL REPORT

**Ordered Items**

JAK2 Exons 12-15

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK2 Exons 12-15</td>
<td>Mut Det PCR</td>
<td>POSITIVE</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A JAK2 mutation was detected. Result must be correlated with other clinical data for the most accurate diagnosis.

**Indications**

POLYCYTHEMIA VERA

**Specimen Type**

Blood

**Nucleotide Change**

c.1849G>T

**Amino Acid Change**

p.V617F

**Background**

JAK2 V617F mutation is detected in patients with polycythemia vera (95%), essential thrombocythemia (50%) and primary myelofibrosis (50%). A small percentage of JAK2 mutation positive patients (3.3%) contain other non-V617F mutations within exons 12 to 15. The detection of a JAK2 gene mutation aids in the specific diagnosis of a myeloproliferative neoplasm, and help distinguish this clonal disease from a benign reactive process.

**Method**

Total RNA was purified from the provided specimen. The JAK2 gene region covering exons 12 to 15 was subjected to reverse-transcription coupled PCR amplification, and bi-directional sequencing to identify sequence variations. This assay has a sensitivity to detect approximately 15% population of cells containing the JAK2 mutations in a background of non-mutant cells.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

**References**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
</table>
| Li Cai, PhD, FACMG  
Director, Molecular Genetics  
LabCorp Center for Molecular Biology and Pathology  
Research Triangle Park, NC  
1-800-533-0567 | 01 | | | | |

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-282-7300